BioPharmSignal logoBioPharmSignal

Biotech News

Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1

Dyne Therapeutics (DYN)Dyne TherapeuticsClinical readout

- Zeleciment basivarsen (z-basivarsen) demonstrated sustained functional improvement across multiple clinical measures in the ongoing ACHIEVE clinical trial - - Expect to complete enrollment in ACHIEVE Registrational Expansion Cohort in early Q2 2026 - WALTHAM, Mass., Jan.

Related news

DYNDyne Therapeutics2026-06-03 11:30 EST

Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)

DYNDyne Therapeutics2026-03-08 22:01 EST

Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)

View all latest news

Dyne Therapeutics

Oligonucleotide Therapeutics Dyne Therapeutics develops targeted oligonucleotide medicines for genetically driven muscle diseases. Its FORCE platform links therapeutic payloads to antibodies intended to improve delivery into muscle tissue. Duchenne Muscular Dystrophy Z-rostudirsen is designed for patients with Duchenne muscular dystrophy...

Recent company news

DYNDyne Therapeutics2026-08-20 20:05 EST

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DYNDyne Therapeutics2026-07-29 20:30 EST

Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

DYNDyne Therapeutics2026-07-28 11:30 EST

Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)

DYNDyne Therapeutics2026-07-24 20:05 EST

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DYNDyne Therapeutics2026-07-23 20:05 EST

Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Stock data

Close
26.10 USD
Market cap
2.85B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States